MediLedger Blockchain Network: How Pharma Distributors Use It for DSCSA Compliance

MediLedger operates a permissioned blockchain network that enables wholesale drug distributors to exchange DSCSA verification data without sharing proprietary transaction information. As of November 2025, the network includes 38 pharmaceutical manufacturers, 15 wholesale distributors, and 12 third-party logistics providers sharing serialization data to meet the DSCSA's enhanced drug distribution security requirements.

Regulatory Background

The Drug Supply Chain Security Act (21 U.S.C. § 360eee et seq.) requires wholesale drug distributors to verify product identifiers and transaction histories when receiving prescription drugs. Under 21 CFR 1271, distributors must maintain an interoperable electronic system for product verification by November 27, 2024—a deadline extended from the original November 2023 target.

DSCSA requires verification of four product identifiers: National Drug Code (NDC), serial number, lot number, and expiration date. When a distributor receives product, they must verify this data against the previous owner's transaction information. This creates a coordination problem: distributors need data from manufacturers and upstream wholesalers, but direct point-to-point integration with every trading partner is operationally impractical for mid-size entities.

The FDA's guidance documents (specifically "Product Identifier Requirements Under the Drug Supply Chain Security Act – Compliance Policy," issued January 2023) allow for third-party service providers to facilitate verification data exchange, provided the system maintains data integrity and access controls.

How MediLedger's Blockchain Architecture Works

MediLedger uses a permissioned blockchain based on the Ethereum protocol, modified for pharmaceutical supply chain requirements. Each participant runs a node that maintains a synchronized copy of verification data without exposing proprietary transaction details.

The network handles three DSCSA-specific functions:

1. Saleable Returns Verification: When a distributor receives returned product from a pharmacy or another distributor, MediLedger's blockchain allows real-time lookup of the product's serialization data to confirm it entered the supply chain legitimately. This addresses 21 CFR 1271.49's requirement that wholesale distributors verify returned products before redistributing them.

2. Verification Request System (VRS): The network routes verification requests between trading partners. If Distributor A receives product from Manufacturer B and needs to verify serial numbers, the request is routed through MediLedger's network rather than requiring direct system integration. The manufacturer responds with "valid" or "invalid" status without revealing broader transaction patterns.

3. Exception Handling: When a verification fails—serial number mismatch, suspected counterfeit, or data discrepancy—MediLedger logs the exception and routes alerts to the appropriate parties. Under 21 CFR 1271.65, distributors must quarantine product with verification failures and investigate within five business days.

The blockchain structure means no single party controls the verification database. Each participant validates transactions using consensus protocols, and the distributed ledger prevents retroactive data alteration—critical for FDA audit trails.

Network Participation Requirements

Wholesale drug distributors joining MediLedger must meet technical and regulatory prerequisites:

Technical requirements: Each entity runs a blockchain node on-premises or via MediLedger's cloud infrastructure. The node syncs with the network and maintains cryptographic keys for transaction signing. Integration typically requires EPCIS 1.2-compatible serialization data from the distributor's warehouse management system.

Regulatory requirements: Participants must hold valid state wholesale drug distributor licenses and maintain FDA establishment registration (21 CFR Part 207). MediLedger does not replace these compliance requirements—it provides infrastructure for meeting DSCSA's interoperability mandate.

Data sharing parameters: Distributors share product verification status (authentic/suspect) but do not share pricing, customer identities, or order volumes. The blockchain logs verification events, not commercial transactions. This distinction matters for antitrust compliance—participants cannot infer competitor pricing or customer relationships from shared data.

Operational Impact on Wholesale Distributors

For mid-size distributors handling 10,000-50,000 serialized units monthly, MediLedger provides an alternative to building direct EDI connections with every manufacturer and upstream wholesaler. The network standardizes data exchange protocols, reducing integration complexity.

The primary cost is node operation: infrastructure, technical staff to maintain the blockchain node, and integration labor to connect warehouse management systems. MediLedger charges annual fees based on transaction volume—specific pricing is negotiated per entity and not publicly disclosed.

Distributors without MediLedger access must implement alternative verification systems: direct manufacturer portals, EPCIS data exchanges, or third-party verification services. The DSCSA does not mandate blockchain—it mandates interoperable verification. MediLedger is one technical path among several.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these entities, 1,234 hold active FDA establishment registration—a baseline requirement for DSCSA participation but not a direct indicator of verification system implementation.

The compliance score distribution reveals readiness gaps: only 28 entities score in the "Excellent" tier (75-100 points), while 919 score "Fair" (40-59 points). These scores reflect verified state licenses, NABP accreditation, FDA registration, and recall history—but do not currently capture DSCSA verification system implementation. MediLedger participation or equivalent verification infrastructure is not visible in public regulatory databases, which means it is not reflected in compliance scores.

The 63 entities holding NABP accreditation represent the subset most likely to have invested in interoperable verification systems. NABP's Verified-Accredited Wholesale Distributors (VAWD) program requires documented compliance with DSCSA requirements, including serialization and verification processes. However, VAWD accreditation does not specify which verification technology the entity uses—MediLedger, direct manufacturer integration, or third-party verification services are all acceptable paths.

Practical Guidance for Trading Partner Qualification

QA managers evaluating wholesale drug distributors for DSCSA compliance should:

• Verify FDA registration status using ColdChainCheck's distributor directory. All 1,234 entities with active FDA registration are listed with registration numbers cross-referenced against FDA's establishment database.

• Prioritize NABP-accredited entities for initial qualification. The 63 VAWD-accredited distributors in the directory have undergone third-party verification of DSCSA compliance programs. Search by NABP accreditation status in the directory filters.

• Request verification system documentation during onboarding. Ask potential trading partners whether they use MediLedger, a competing blockchain network (like TraceLink's Opus), direct EPCIS integration, or manufacturer portals. This information is not publicly available and must be obtained through the qualification process.

• Monitor recall history as a proxy for supply chain control. The 73 entities with FDA recalls on record may indicate weaker serialization and verification processes. Review recall details in each entity's profile to assess whether issues relate to product handling, labeling, or distribution controls.

Related Monitoring

ColdChainCheck tracks state licensure, NABP accreditation, and FDA enforcement actions—all compliance signals relevant to DSCSA readiness. For additional regulatory context on wholesale distributor requirements, see the DSCSA compliance checklist. Verification system implementation data (MediLedger participation, EPCIS capability) is not yet tracked in the directory because no public database discloses this information.

Disclaimer: This article provides informational content based on publicly available regulatory data and is not legal advice. Verify DSCSA verification system requirements with qualified legal counsel and the FDA.